Arrowhead’s Plozasiran Shows Reductions in Triglycerides and Cholesterol in Phase 2 Study
Arrowhead Pharmaceuticals Presents New Phase 2 Data of Plozasiran in Patients with Mixed Hyperlipidemia
Business Wire
- Plozasiran significantly lowered triglyceride levels with commensurate reductions in APOC3,